ETILX Mutual Fund Forecast & Price Targets

Compare

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

ETILX Analyst Rating

Moderate Buy

66 Buy

9 Hold

0 Sell

Based on the consensus analyst ratings on 75 stocks held in ETILX.

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

ETILX Analyst Price Target

Average Price Target

$62.07

Based on 75 Wall Street analysts offering 12 month price targets to Eventide Gilead Fund Institutional Class holdings in the last 3 months. The average price target is $62.07 with a high forecast of $76.31 and a low forecast of $49.03. The average price target represents a 29.80% change from the last price of $47.82.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"46":"$46","77":"$77","53.75":"$53.8","61.5":"$61.5","69.25":"$69.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":76.311,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$76.31</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":62.072,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$62.07</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":49.028,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$49.03</span>\n  </div></div>","useHTML":true}}],"tickPositions":[46,53.75,61.5,69.25,77],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Nov<br/>2024","9":"Feb<br/>2025","12":"May<br/>2025","25":"May<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n              \n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,49.25,51.33161538461538,53.41323076923077,55.494846153846154,57.576461538461544,59.658076923076926,61.73969230769231,63.8213076923077,65.90292307692309,67.98453846153846,70.06615384615385,72.14776923076923,74.22938461538462,{"y":76.311,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,49.25,50.23630769230769,51.22261538461539,52.20892307692308,53.19523076923077,54.181538461538466,55.167846153846156,56.15415384615385,57.14046153846154,58.126769230769234,59.113076923076925,60.09938461538462,61.08569230769231,{"y":62.072,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,49.25,49.23292307692308,49.21584615384615,49.19876923076923,49.18169230769231,49.16461538461538,49.14753846153846,49.13046153846154,49.11338461538462,49.09630769230769,49.07923076923077,49.06215384615385,49.04507692307692,{"y":49.028,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":49.47,"date":1714521600000,"info":"<div>Price: <b>$49<b/></div>","marker":{"enabled":true,"symbol":"circle"}},{"y":48.05,"date":1717372800000,"info":"<div>Price: <b>$48<b/></div>","marker":{"enabled":true,"symbol":"circle"}},{"y":48.99,"date":1719792000000,"info":"<div>Price: <b>$49<b/></div>","marker":{"enabled":true,"symbol":"circle"}},{"y":48.98,"date":1722470400000,"info":"<div>Price: <b>$49<b/></div>","marker":{"enabled":true,"symbol":"circle"}},{"y":49.79,"date":1725321600000,"info":"<div>Price: <b>$50<b/></div>","marker":{"enabled":true,"symbol":"circle"}},{"y":50.86,"date":1727740800000,"info":"<div>Price: <b>$51<b/></div>","marker":{"enabled":true,"symbol":"circle"}},{"y":50.52,"date":1730419200000,"info":"<div>Price: <b>$51<b/></div>","marker":{"enabled":true,"symbol":"circle"}},{"y":55.01,"date":1733097600000,"info":"<div>Price: <b>$55<b/></div>","marker":{"enabled":true,"symbol":"circle"}},{"y":51.89,"date":1735776000000,"info":"<div>Price: <b>$52<b/></div>","marker":{"enabled":true,"symbol":"circle"}},{"y":55.34,"date":1738540800000,"info":"<div>Price: <b>$55<b/></div>","marker":{"enabled":true,"symbol":"circle"}},{"y":50.82,"date":1740960000000,"info":"<div>Price: <b>$51<b/></div>","marker":{"enabled":true,"symbol":"circle"}},{"y":47.37,"date":1743465600000,"info":"<div>Price: <b>$47<b/></div>","marker":{"enabled":true,"symbol":"circle"}},{"y":49.25,"date":1746057600000,"info":"<div>Price: <b>$49<b/></div>","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$76.31

Average Price Target$62.07

Lowest Price Target$49.03

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

ETILX Stocks With Highest Upside Potential

xxxxxxxxxxxxxxxxxxxxxxxxxxx

ZNTL

Zentalis Pharmaceuticals Inc

5 Buy

4 Hold

0 Sell

Moderate Buy

$7.25

xxxxxxxxxxxxxxxxxxxxxxxxxxx

CLDX

Celldex Therapeutics

9 Buy

1 Hold

0 Sell

Strong Buy

$60.78

xxxxxxxxxxxxxxxxxxxxxxxxxxx

ARDX

Ardelyx Inc

8 Buy

2 Hold

0 Sell

Strong Buy

$10.55

xxxxxxxxxxxxxxxxxxxxxxxxxxx

SRRK

Scholar Rock Holding

8 Buy

0 Hold

0 Sell

Strong Buy

$50.17

xxxxxxxxxxxxxxxxxxxxxxxxxxx

TTD

Trade Desk

22 Buy

7 Hold

1 Sell

Moderate Buy

$91.65

ETILX Stocks With Highest Downside Potential

xxxxxxxxxxxxxxxxxxxxxxxxxxx

Trane Technologies Plc

4 Buy

7 Hold

1 Sell

Hold

$399.90

xxxxxxxxxxxxxxxxxxxxxxxxxxx

CRWD

Crowdstrike Holdings

34 Buy

3 Hold

0 Sell

Strong Buy

$423.62

xxxxxxxxxxxxxxxxxxxxxxxxxxx

IRTC

Irhythm Technologies

11 Buy

0 Hold

0 Sell

Strong Buy

$139.10

xxxxxxxxxxxxxxxxxxxxxxxxxxx

TMDX

Transmedics Group

4 Buy

3 Hold

0 Sell

Moderate Buy

$98.00

xxxxxxxxxxxxxxxxxxxxxxxxxxx

XMTR

Xometry, Inc.

7 Buy

2 Hold

1 Sell

Moderate Buy

$31.25

ETILX Mutual Fund FAQ

What is ETILX’s average 12-month price target, according to analysts?

Based on analyst ratings, Eventide Gilead Fund Institutional Class’s 12-month average price target is 62.07.

What is ETILX’s upside potential, based on the analysts’ average price target?

Currently there's no upside potential for ETILX, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is ETILX a Buy, Sell or Hold?

Eventide Gilead Fund Institutional Class has a consensus rating of Moderate Buy which is based on 66 buy ratings, 9 hold ratings and 0 sell ratings.

What is Eventide Gilead Fund Institutional Class’s price target?

The average price target for Eventide Gilead Fund Institutional Class is 62.07. This is based on 75 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $76.31 ,the lowest forecast is $49.03. The average price target represents N/A Increase from the current price of N/A.

What do analysts say about Eventide Gilead Fund Institutional Class?

Eventide Gilead Fund Institutional Class’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 75 Wall Streets Analysts.

How can I buy shares of ETILX?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing